MA39751B1 - Antibody compositions for the treatment of tumors - Google Patents

Antibody compositions for the treatment of tumors

Info

Publication number
MA39751B1
MA39751B1 MA39751A MA39751A MA39751B1 MA 39751 B1 MA39751 B1 MA 39751B1 MA 39751 A MA39751 A MA 39751A MA 39751 A MA39751 A MA 39751A MA 39751 B1 MA39751 B1 MA 39751B1
Authority
MA
Morocco
Prior art keywords
present
antigen
binding
bispecific antibodies
bispecific
Prior art date
Application number
MA39751A
Other languages
French (fr)
Inventor
Gavin Thurston
Eric Smith
Jessica R Kirshner
Samuel Davis
Bindu Varghese
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2015/021322 external-priority patent/WO2015143079A1/en
Publication of MA39751B1 publication Critical patent/MA39751B1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps bispécifiques qui se lient à cd3 et à des antigènes tumoraux et leurs méthodes d'utilisation. Selon certains modes de réalisation, les anticorps bispécifiques selon la présente invention présentent des fonctions effectrices réduites et possèdent un profil de liaison unique par rapport aux récepteurs fc?. Les anticorps bispécifiques sont modifiés pour induire de façon efficace la mort à médiation par les lymphocytes t de cellules tumorales. Selon certains modes de réalisation, la présente invention concerne des molécules de liaison à un antigène bispécifiques comprenant un premier domaine de liaison à un antigène qui se lie spécifiquement au cd3 humain, une seconde molécule de liaison à un antigène qui se lie spécifiquement au cd20 humain, et un domaine fc qui se lie à des récepteurs fc? Avec un mode de liaison spécifique. Dans certains modes de réalisation, les molécules de liaison à un antigène bispécifiques selon la présente invention sont susceptibles d'inhiber la croissance de cellules bêta ou de tumeurs de mélanome exprimant cd20. Les anticorps bispécifiques selon la présente invention sont utiles pour le traitement de divers cancers ainsi que d'autres maladies et troubles associés au cd20.The present invention relates to bispecific antibodies that bind cd3 and tumor antigens and methods of their use. According to some embodiments, the bispecific antibodies according to the present invention exhibit reduced effector functions and possess a unique binding profile relative to fc? Receptors. The bispecific antibodies are engineered to efficiently induce T cell mediated death of tumor cells. In some embodiments, the present invention relates to bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds to human cd3, a second antigen-binding molecule that specifically binds to human cd20 , and an fc domain that binds to fc receptors? With a specific binding mode. In certain embodiments, the bispecific antigen-binding molecules according to the present invention are capable of inhibiting the growth of beta cells or melanoma tumors expressing cd20. The bispecific antibodies according to the present invention are useful for the treatment of various cancers as well as other diseases and disorders associated with cd20.

MA39751A 2014-03-19 2015-03-18 Antibody compositions for the treatment of tumors MA39751B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461955663P 2014-03-19 2014-03-19
PCT/US2015/021322 WO2015143079A1 (en) 2014-03-19 2015-03-18 Antibody compositions for tumor treatment

Publications (1)

Publication Number Publication Date
MA39751B1 true MA39751B1 (en) 2019-11-29

Family

ID=58699943

Family Applications (2)

Application Number Title Priority Date Filing Date
MA50374A MA50374B1 (en) 2014-03-19 2015-03-18 Antibody compositions for the treatment of tumors
MA39751A MA39751B1 (en) 2014-03-19 2015-03-18 Antibody compositions for the treatment of tumors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA50374A MA50374B1 (en) 2014-03-19 2015-03-18 Antibody compositions for the treatment of tumors

Country Status (3)

Country Link
AR (1) AR099798A1 (en)
HR (1) HRP20210615T1 (en)
MA (2) MA50374B1 (en)

Also Published As

Publication number Publication date
AR099798A1 (en) 2016-08-17
MA50374A (en) 2020-01-15
MA50374B1 (en) 2021-06-30
HRP20210615T1 (en) 2021-05-28

Similar Documents

Publication Publication Date Title
MA42542B1 (en) Molecules Binding to pd-1 and Corresponding Methods of Use
MA39313A1 (en) Anti-egfrviii antibodies and their uses in the treatment of various cancers
MA35035B1 (en) POLYPEPTIDE ANTIBODIES THAT ANTAGONIZE CD40
MA40041A (en) ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
MA40801A1 (en) Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
MA42935B1 (en) Optimized anti-cd3 bispecific antibodies and their uses
MA46708B1 (en) Anti-pd1 antibodies and their uses
MA44312A (en) ANTIBODIES AND THEIR METHODS OF USE
MA42622B1 (en) LIAISONS IN TIGIT AND THEIR USES
MX2019013033A (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof.
MX2020004410A (en) Antibody compositions for tumor treatment.
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MA38498B1 (en) Anti-lag-3 binding proteins
EP3214096A3 (en) Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
MA33402B1 (en) COMPOSITIONS AND METHODS FOR TARGETING COMPLEMENT C3B PROTEIN BY ANTIBODIES
MA33387B1 (en) POLYPEPTIDES AND PROCESSING METHOD
MX2021005048A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof.
ZA202107047B (en) Heterodimeric antibodies that bind enpp3 and cd3
EA202192146A1 (en) ANTIBODIES FOR CLAUDIN 6 AND THEIR APPLICATION
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
MX2023010499A (en) Heterodimeric antibodies that bind cd3 and cldn6.
MA39751B1 (en) Antibody compositions for the treatment of tumors
MA48751B1 (en) ANTI-CD19 ANTIBODY TREATMENT PARADIGM AND VENETOCLAX COMBINATION TREATMENT
MX2022001882A (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40.